BCI-540 · Evidence-based safety and harm-reduction overview.
| Also known as | BCI-540 |
| Category | Nootropic |
| chemical_family | Racetam analog, distinct HACU-targeting modification |
| developer_origin | Japan (BCI Pharma) |
| US legal status | Not FDA-approved; sold as research chemical in gray market. No approved therapeutic use in the United States. |
Synthetic racetam analog, proposed to influence acetylcholine synthesis and high-affinity choline uptake. Coluracetam is theorized to stimulate HACU (high-affinity choline uptake) pathways, a rate-limiting step in acetylcholine synthesis. Development was discontinued in later stages but remains sold as research chemical.
Proposed to selectively enhance HACU, a sodium and chloride-dependent transporter in cholinergic neurons. May also modulate phospholipid metabolism and cell signaling. Animal data suggests potential mitochondrial effects, but human evidence is absent.
Developed in the 1990s by BCI Pharma (Japan) as a novel nootropic targeting acetylcholine synthesis. Clinical development discontinued; never reached FDA evaluation or widespread pharmaceutical approval outside Japan and South Korea.
Minimal human clinical data; mostly animal studies and small preliminary trials. Evidence does not meet regulatory standards. Japanese and Korean literature contains more data than Western publications; translation and independent verification lacking.
Early clinical trials employed 100-300 mg daily in divided doses. Current gray-market products typically range 75-300 mg per capsule; no validated dosing protocol exists for human use.
This is general research/context information, not medical advice or a recommended protocol.
Anecdotal reports of stacking with choline and uridine based on animal mechanistic data, but no human studies validate this. Often avoided with other experimental racetams due to unknown interaction profiles.
Alpha-GPC (choline alphoscerate). Legal dietary supplement with moderate evidence for mood and cognition support; better-regulated and more bioavailable choline source.
See our recommended pickIf you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.
Compare testing optionsIt is sold online but is not FDA-approved and not a recognized dietary supplement. Legal status is ambiguous and risk is high.
Evidence is from animal studies and very small preliminary human trials. No robust clinical data supports cognitive benefits yet.
Coluracetam specifically targets acetylcholine synthesis via HACU enhancement, whereas other racetams affect general membrane fluidity or other mechanisms.
No, it is proposed to enhance choline uptake into specific neurons rather than just providing choline as a precursor.
BCI Pharma in Japan developed it but discontinued clinical advancement; it remains sold as research chemical but no longer pursued as a pharmaceutical.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.